Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 2
2005 3
2006 7
2007 5
2008 5
2009 8
2010 4
2011 3
2012 1
2013 2
2015 2
2016 1
2017 2
2018 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Postmenopausal hormone therapy.
Grady D, Barrett-Connor E. Grady D, et al. BMJ. 2007 Apr 28;334(7599):860-1. doi: 10.1136/bmj.39188.594282.80. BMJ. 2007. PMID: 17463421 Free PMC article.
In Reply.
Huang AJ, Ganz P, Grady D, Cummings SR. Huang AJ, et al. Among authors: grady d. Menopause. 2017 Jan;24(1):120. doi: 10.1097/GME.0000000000000820. Menopause. 2017. PMID: 28002350 No abstract available.
Efficacy of Continuous Transdermal Nitroglycerin for Treating Hot Flashes by Inducing Nitrate Cross-tolerance in Perimenopausal and Postmenopausal Women: A Randomized Clinical Trial.
Huang AJ, Cummings SR, Ganz P, Schembri M, Raghunathan H, Vittinghoff E, Gibson CJ, Grady D. Huang AJ, et al. Among authors: grady d. JAMA Intern Med. 2023 Aug 1;183(8):776-783. doi: 10.1001/jamainternmed.2023.1977. JAMA Intern Med. 2023. PMID: 37273224 Clinical Trial.
IMPORTANCE: Due to the potential risks of long-term systemic estrogen therapy, many menopausal women are interested in nonhormonal treatments for vasomotor symptoms. ...OBJECTIVE: To determine whether uninterrupted administration of transdermal nitroglycerin (NTG) to induc …
IMPORTANCE: Due to the potential risks of long-term systemic estrogen therapy, many menopausal women are interested in nonhormonal tr …
Oophorectomy as a risk factor for coronary heart disease.
Jacoby VL, Grady D, Sawaya GF. Jacoby VL, et al. Among authors: grady d. Am J Obstet Gynecol. 2009 Feb;200(2):140.e1-9. doi: 10.1016/j.ajog.2008.08.045. Epub 2008 Nov 18. Am J Obstet Gynecol. 2009. PMID: 19019330 Free PMC article. Review.
STUDY DESIGN: We searched PubMed, EMBASE, meeting abstracts, and reference lists for studies that compared women with BSO at the time of hysterectomy with: (1) women with hysterectomy and ovarian conservation, (2) naturally menopausal women, (3) premenopausal women, or (4) …
STUDY DESIGN: We searched PubMed, EMBASE, meeting abstracts, and reference lists for studies that compared women with BSO at the time of hys …
The rise and fall of menopausal hormone therapy.
Barrett-Connor E, Grady D, Stefanick ML. Barrett-Connor E, et al. Among authors: grady d. Annu Rev Public Health. 2005;26:115-40. doi: 10.1146/annurev.publhealth.26.021304.144637. Annu Rev Public Health. 2005. PMID: 15760283 Review.
HT improves other symptoms including sleep and quality of life in women who have menopause symptoms. In the Women's Health Initiative controlled clinical trials, both estrogen therapy (ET) and estrogen plus progestin therapy (EPT) reduced fracture risk, neither reduced the …
HT improves other symptoms including sleep and quality of life in women who have menopause symptoms. In the Women's Health Initiative …
Discontinuation of postmenopausal hormone therapy.
Grady D, Sawaya GF. Grady D, et al. Am J Med. 2005 Dec 19;118 Suppl 12B:163-5. doi: 10.1016/j.amjmed.2005.09.051. Am J Med. 2005. PMID: 16414343
Current guidelines recommend that postmenopausal hormone therapy (HT) be used primarily for treatment of vasomotor and urogenital symptoms associated with the menopausal transition and that women use the lowest effective dose for the shortest time necessary. ...
Current guidelines recommend that postmenopausal hormone therapy (HT) be used primarily for treatment of vasomotor and urogenital symptoms a …
Postmenopausal hormone treatment.
Hulley S, Grady D. Hulley S, et al. Among authors: grady d. JAMA. 2009 Jun 17;301(23):2493-5. doi: 10.1001/jama.2009.847. JAMA. 2009. PMID: 19531791 No abstract available.
53 results